Wohlfeiler M, Henegar C, Schulman K, et al. Predictors of virologic success in an older ART naïve HIV population [2127]. Presented at: Infectious Diseases Week 2016; New Orleans, LA, USA
Research Category: Abstracts and Posters
HIV/Hepatitis C co-infected patients are significantly more complex to manage than HIV mono-infected patients in a large cohort of treatment-naïve, HIV-positive individuals
Dieterich D, Fusco J, Henegar C, et al. HIV/Hepatitis C co-infected patients are significantly more complex to manage than HIV mono-infected patients in a large cohort of treatment-naïve, HIV-positive individuals [P260]. Presented at: HIV Drug Therapy Glasgow Meeting 2016; Glasgow, UK
Trends in HIV antiretroviral tablet burden in treatment-naïve patients in the United States
Lackey P, Schulman K, Henegar C, D’Amico R, Zelt S, Fusco G. Trends in HIV antiretroviral tablet burden in treatment-naïve patients in the United States. Presented at: The Academy of Managed Care Pharmacy (AMCP) Nexus Meeting 2016; National Harbor, MD, USA. Silver Award Recipient
INSTI In-Class Switching on Continued Viral Suppression in the OPERA Cohort
Wohlfeiler M, Carpio F, Lackey P, et al. INSTI In-Class Switching on Continued Viral Suppression in the OPERA Cohort [953]. Presented at: Conference on Retroviruses and Opportunistic Infections 2016; Boston, MA, USA
Virologic effectiveness of abacavir/lamivudine with darunavir versus other protease inhibitors in treatment-experienced HIV-infected patients in clinical practice
Lackey P, Mills A, Carpio F, et al. Virologic effectiveness of abacavir/lamivudine with darunavir versus other protease inhibitors in treatment-experienced HIV-infected patients in clinical practice [1086]. Presented at: Infectious Diseases Week 2015; San Diego, CA, USA
Survival in patients coinfected with HIV and Hepatitis C: Is there a CD4 threshold
Fultz SL, Chang CCH, Skanderson M, Butt AA, Rigsby MO, Fusco GP, Dieterich DT, Becker SL, Simberkoff M, Rabeneck L, Rodriguez-Barradas M, Justice AC. Survival in patients coinfected with HIV and Hepatitis C: Is there a CD4 threshold. Poster. XV International AIDS Conference, July 2004, Bangkok, Thailand
Utilization patterns of raltegravir within the OPERA database
DeJesus E, Pierone G, Lackey P, et al. Utilization patterns of raltegravir within the OPERA database. Presented at: 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) 2009; Philadelphia, PA, USA
Dynamics of immunologic decline and virological rebound during treatment interruption in chronic HIV disease
Mera R, Most B, Balu RB, Fusco JS. Dynamics of immunologic decline and virological rebound during treatment interruption in chronic HIV disease. 4593. Poster. XV International Aids Conference, July 2004, Bangkok, Thailand
Use of novel methodology for a risk management program examining risk of abacavir hypersensitivity reaction, rechallenge reaction, hospitalization, and death
Gibbons DC, Baker RK, Bartlett JA, Cutrell AG, Eron JJ, Fusco GP, Fusco JS, Gallant JE, Mole L, Moore RD, Nordstrom BL, Rosenberg DM, Walker AM, White AD, Wood KC. Use of novel methodology for a risk management program examining risk of abacavir hypersensitivity reaction, rechallenge reaction, hospitalization, and death. Poster. 19th International Conference on Pharmacoepidemiology and the 1st International Conference on Therapeutic Risk Management. August 2003, Philadelphia, PA
Moderate viremia and HIV disease progression
Raffanti SR, Fusco JS, Becker SL, Sherrill BH, Hansen NI, Justice AC, D’Aquila R, Mangialardi WJ, Fusco GP. Moderate viremia and HIV disease progression. Poster. LB35, International AIDS Society Conference. July 2003, Paris, France.